US Pharma MarketingExclusive: Sanofi taps new startup ScionxBio for long-acting RNA
ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to share financial details. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
ScionxBio has inked a deal with French drugmaker Sanofi — its first partnership since splitting from parent company Eleven Therapeutics a few months ago.
Under the agreement, ScionxBio will screen Sanofi’s mRNA candidates through its so-called ...
Source: Endpoints News